JW Pharmaceutical·VORONOI, Joint develpoment of targeting STAT3 in anticancer field – mk.co.kr

On December 2, JW Pharmaceutical inked a deal with Korean biotech startup Voronoi to develop next-generation innovative new drugs.
It plans to develop a next-generation innovative new drug with global competitiveness by combining JW Pharmaceutical’s small molecule anticancer drug candidate of targeting STAT3 with Voronoi’s protein decomposition technology ‘Protein Degrader(PROTAC; Proteolysis-targeting chimera)’.